HepQuant’s Greg Everson, MD, to Speak at AASLD/FDA Conference on Drug-Induced Liver Injury (DILI)
DENVER (April 14th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that it will present at the 2021 AASLD/FDA Conference on Drug-Induced Liver Injury (DILI): New Developments and Innovations in Patients with Underlying Liver Disease, Cancer or COVID-19.
The Virtual Conference will be held April 20 – 22. HepQuant CEO and Chief Medical Officer Greg Everson, MD, will present on the topic “Non-invasive Quantitative Liver Tests for Disease Activity and Fibrosis: Can They Reliably Guide Optimal Treatment Regimens During the Progression of CLD,” on Tuesday, April 20, 11:30 a.m. to 11:50 a.m., Eastern Time. An archive of the presentation and Q&A session will be available following the presentation.
The AASLD (American Association for the Study of Liver Disease) / FDA DILI Conference will connect international academic, industry and government participants who are dedicated to the study of DILI in chronic liver disease and cancer with topics spanning into innovative tools in the assessment of hepatotoxic risk and the growing number of best practice consensus reports by public-private partnerships management of DILI in different study populations. Additionally, the meeting will have planned sessions on the impact of COVID-19 in the evaluation and management of liver disease. With virtual communication tools, the conference will promote interactivity between faculty and the audience by panel discussions and a live poster session.
Headquartered in Denver, Colorado, HepQuant, LLC, is a privately-held diagnostics company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA guidelines for investigational device exemptions (IDEs). For additional information, visit www.hepquant.com.
Investor and Business Inquiries: Bradley C. Everson | Chief Business Development Officer
Ph: (303) 923-2150 | [email protected]